Table I.
Description of the study population and univariate risk factors for recurrence: characteristics of patients and tumours
| Characteristics | Study population* n = 4,773 | Recurrence in BCC |
p-value | Recurrence in SCC |
p-value | ||
|---|---|---|---|---|---|---|---|
| No n = 4,248 (%) | Yes n = 154 (%) | No n = 330 (%) | Yes n = 41 (%) | ||||
| Patients | |||||||
| Sex (male), n (%) | 2,458 (52) | 2,121 (50) | 79 (51) | 0.7385 | 225 (68) | 33 (80) | 0.1064 |
| Age, years, median (IQR) | 70.8 (59.3-79.5) | 70.6 (59.4–79.5) | 74.5 (66.5–80.7) | 0.0029 | 76.9 (65.8–83.1) | 75 (69.5–81.9) | 0.8286 |
| Immunosuppression, n (%) | 149 (3) | 109 (3) | 8 (5) | 0.0658 | 22 (7) | 10 (24) | 0.0010 |
| Diabetes mellitus, n (%) | 562 (12) | 478 (11) | 20 (14) | 0.4034 | 57 (18) | 7 (17) | 0.9139 |
| Multiple tumour syndromes, n (%) | 113 (2) | 100 (2) | 3 (2) | 1.0000 | 10 (3) | 0 (0) | 0.6100 |
| Tumours | |||||||
| Time since appearance, months, median (IQR) | 14.3 (6.8–34.2) | 14.3 (6.7–33.4) | 19.3 (8.4–37) | 0.0283 | 9.2 (5–19.5) | 9.3 (4.1–28.1) | 0.8384 |
| Size, mm, n (%) | 0.3299 | 0.1679 | |||||
| < 10 | 1,929 (41) | 1,765 (42) | 58 (38) | NA | 98 (31) | 8 (20) | NA |
| ≥ 10 | 2,746 (59) | 2,398 (58) | 93 (62) | NA | 223 (69) | 32 (80) | NA |
| Type, n (%) | 0.0000 | 0.0295 | |||||
| Primary | 3,008 (63) | 2,720 (64) | 70 (45) | NA | 201 (61) | 17 (41) | NA |
| Recurrent | 979 (21) | 857 (20) | 47 (31) | NA | 61 (18) | 14 (34) | NA |
| Persistent | 786 (16) | 671 (16) | 37 (24) | NA | 68 (21) | 10 (24) | NA |
| Zone, n (%) | 0.0482 | 0.4111 | |||||
| H-Area | 3,813 (80) | 3,441 (82) | 114 (74) | NA | 232 (71) | 26 (63) | NA |
| M-Area | 901 (19) | 756 (18) | 39 (25) | NA | 91 (28) | 15 (37) | NA |
| L-Area | 26 (1) | 20 (0) | 1 (1) | NA | 5 (2) | 0 (0) | NA |
| Histologically aggressive, n (%) | 3,402 (71) | 3,028 (71) | 104 (68) | 0.3132 | 239 (72) | 31 (76) | 0.6656 |
| Previous surgical treatments, n (%) | 856 (18) | 719 (17) | 48 (31) | 0.0000 | 77 (23) | 12 (29) | 0.4074 |
| Previous non-surgical treatments, n (%) | 232 (5) | 190 (4) | 14 (9) | 0.0058 | 22 (7) | 6 (15) | 0.1065 |
*
Some proportions cannot be calculated from the table due to few missing data on the variable.
BCC: basal cell carcinoma; SCC: squamous cell carcinoma; NA: non-applicable; IQR: interquartile range. Bold indicates statistically significant results.